Clinical Trials Logo

Pearson Syndrome clinical trials

View clinical trials related to Pearson Syndrome.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06017869 Recruiting - Clinical trials for Mitochondrial Diseases

Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-201 in Pediatric Patients With Pearson Syndrome

Start date: July 31, 2023
Phase: Phase 1
Study type: Interventional

Primary Mitochondrial diseases are a clinically and genetically heterogeneous group of disorders caused by mutations in genes encoded by nuclear Deoxyribonucleic Acid (DNA) or by mutations and/or deletions in the mitochondrial DNA (mtDNA). While some mitochondrial disorders only affect a single organ (e.g., the eye in Leber hereditary optic neuropathy [LHON]), many involve multiple organs. Mitochondrial disorders may present at any age and a frequent feature is the increasing number of organs involved in the course of the disease. Minovia Therapeutics Ltd. ("Minovia") is a biotech company developing novel therapeutics based on its mitochondrial augmentation technology (MAT). MNV-201 is a cell therapy produced by MAT that consists of the participant's autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) enriched with allogeneic placental-derived mitochondria, manufactured in Minovia's GMP facility.

NCT ID: NCT05554835 Recruiting - MDS Clinical Trials

Global Registry and Natural History Study for Mitochondrial Disorders

Start date: February 1, 2009
Phase:
Study type: Observational [Patient Registry]

The main goal of the project is provision of a global registry for mitochondrial disorders to harmonize previous national registries, enable world-wide participation and facilitate natural history studies, definition of outcome measures and conduction of clinical trials.

NCT ID: NCT05029843 Recruiting - Pearson Syndrome Clinical Trials

SLSMDS Natural History Study

Start date: March 16, 2021
Phase:
Study type: Observational

The Single Large-Scale mtDNA Deletion Sydrome: Natural History Study (PS-NHS) aims to collect data on standardized clinical outcomes, store data on the Champ Foundation Registry (CFR) and make this data available to researchers, clinicians, and industry partners who are studying SLSMDS to answer questions regarding the disease, including its causes, potential treatments, and other topics. A secondary aim is to analyze the data to understand research questions relating to the natural history of SLSMDS.